239 related articles for article (PubMed ID: 28509765)
1. Multicenter, real-life experience with checkpoint inhibitors and targeted therapy agents in advanced melanoma patients in Switzerland.
Mangana J; Cheng PF; Kaufmann C; Amann VC; Frauchiger AL; Stögner V; Held U; von Moos R; Michielin O; Braun RP; Levesque MP; Goldinger SM; Dummer R
Melanoma Res; 2017 Aug; 27(4):358-368. PubMed ID: 28509765
[TBL] [Abstract][Full Text] [Related]
2. Outcomes in Melanoma Patients Treated with BRAF/MEK-Directed Therapy or Immune Checkpoint Inhibition Stratified by Clinical Trial versus Standard of Care.
Goldman C; Tchack J; Robinson EM; Han SW; Moran U; Polsky D; Berman RS; Shapiro RL; Ott PA; Osman I; Zhong H; Pavlick AC; Wilson MA
Oncology; 2017; 93(3):164-176. PubMed ID: 28601879
[TBL] [Abstract][Full Text] [Related]
3. Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017.
Ugurel S; Röhmel J; Ascierto PA; Flaherty KT; Grob JJ; Hauschild A; Larkin J; Long GV; Lorigan P; McArthur GA; Ribas A; Robert C; Schadendorf D; Garbe C
Eur J Cancer; 2017 Sep; 83():247-257. PubMed ID: 28756137
[TBL] [Abstract][Full Text] [Related]
4. Survival of patients with metastatic melanoma and brain metastases in the era of MAP-kinase inhibitors and immunologic checkpoint blockade antibodies: A systematic review.
Spagnolo F; Picasso V; Lambertini M; Ottaviano V; Dozin B; Queirolo P
Cancer Treat Rev; 2016 Apr; 45():38-45. PubMed ID: 26975020
[TBL] [Abstract][Full Text] [Related]
5. Metastatic acral lentiginous melanoma in a tertiary referral center in Switzerland: a systematic analysis.
Häfliger EM; Ramelyte E; Mangana J; Kunz M; Kazakov DV; Dummer R; Cheng PF
Melanoma Res; 2018 Oct; 28(5):442-450. PubMed ID: 29847461
[TBL] [Abstract][Full Text] [Related]
6. Survival of melanoma patients treated with targeted therapy and immunotherapy after systematic upfront control of brain metastases by radiosurgery.
Gaudy-Marqueste C; Dussouil AS; Carron R; Troin L; Malissen N; Loundou A; Monestier S; Mallet S; Richard MA; Régis JM; Grob JJ
Eur J Cancer; 2017 Oct; 84():44-54. PubMed ID: 28783540
[TBL] [Abstract][Full Text] [Related]
7. Association of First-in-Class Immune Checkpoint Inhibition and Targeted Therapy With Survival in Patients With Stage IV Melanoma.
Sinnamon AJ; Neuwirth MG; Gimotty PA; Gangadhar TC; Amaravadi RK; Schuchter LM; Karakousis GC
JAMA Oncol; 2018 Jan; 4(1):126-128. PubMed ID: 29145547
[TBL] [Abstract][Full Text] [Related]
8. The Systemic Management of Advanced Melanoma in 2016.
Heppt MV; Dietrich C; Graf SA; Ruzicka T; Tietze JK; Berking C
Oncol Res Treat; 2016; 39(10):635-642. PubMed ID: 27710977
[TBL] [Abstract][Full Text] [Related]
9. Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond.
Menzies AM; Long GV
Eur J Cancer; 2013 Oct; 49(15):3229-41. PubMed ID: 23870385
[TBL] [Abstract][Full Text] [Related]
10. [Immunotherapies and melanoma].
Routier É; Robert C; Mateus C
Bull Cancer; 2014 Dec; 101 Suppl 2():S13-24. PubMed ID: 25776763
[TBL] [Abstract][Full Text] [Related]
11. Survival of patients with advanced metastatic melanoma: The impact of novel therapies.
Ugurel S; Röhmel J; Ascierto PA; Flaherty KT; Grob JJ; Hauschild A; Larkin J; Long GV; Lorigan P; McArthur GA; Ribas A; Robert C; Schadendorf D; Garbe C
Eur J Cancer; 2016 Jan; 53():125-34. PubMed ID: 26707829
[TBL] [Abstract][Full Text] [Related]
12. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
[TBL] [Abstract][Full Text] [Related]
13. Sarcoid-like reactions in patients receiving modern melanoma treatment.
Dimitriou F; Frauchiger AL; Urosevic-Maiwald M; Naegeli MC; Goldinger SM; Barysch M; Franzen D; Kamarachev J; Braun R; Dummer R; Mangana J
Melanoma Res; 2018 Jun; 28(3):230-236. PubMed ID: 29485531
[TBL] [Abstract][Full Text] [Related]
14. Nivolumab: A Review in Advanced Melanoma.
Scott LJ
Drugs; 2015 Aug; 75(12):1413-24. PubMed ID: 26220912
[TBL] [Abstract][Full Text] [Related]
15. Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma.
Ribas A; Hamid O; Daud A; Hodi FS; Wolchok JD; Kefford R; Joshua AM; Patnaik A; Hwu WJ; Weber JS; Gangadhar TC; Hersey P; Dronca R; Joseph RW; Zarour H; Chmielowski B; Lawrence DP; Algazi A; Rizvi NA; Hoffner B; Mateus C; Gergich K; Lindia JA; Giannotti M; Li XN; Ebbinghaus S; Kang SP; Robert C
JAMA; 2016 Apr; 315(15):1600-9. PubMed ID: 27092830
[TBL] [Abstract][Full Text] [Related]
16. New therapeutic options in systemic treatment of advanced cutaneous melanoma.
Mackiewicz-Wysocka M; Zolnierek J; Wysocki PJ
Expert Opin Investig Drugs; 2013 Feb; 22(2):181-90. PubMed ID: 23215674
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of the long-term adjuvant treatment of primary intermediate- to high-risk malignant melanoma (UICC/AJCC stage II and III) with a standardized fermented European mistletoe (Viscum album L.) extract. Results from a multicenter, comparative, epidemiological cohort study in Germany and Switzerland.
Augustin M; Bock PR; Hanisch J; Karasmann M; Schneider B
Arzneimittelforschung; 2005; 55(1):38-49. PubMed ID: 15727163
[TBL] [Abstract][Full Text] [Related]
18. Kinase inhibitors and immune check-point blockade for the treatment of metastatic melanoma and advanced cancer: synergistic or antagonistic?
Luke JJ; Ott PA
Expert Opin Pharmacother; 2013 Dec; 14(18):2457-62. PubMed ID: 24138302
[TBL] [Abstract][Full Text] [Related]
19. Preferences of physicians for treatment-related toxicity vs. recurrence in melanoma (GERMELATOX-A): the doctors' perspective.
Kähler KC; Gutzmer R; Angela Y; Livingstone E; Lodde G; Meiss F; Rafei-Shamsabadi DA; Weyer-Fahlbusch SS; Nashan D; Loquai C; Hassel JC; Sachse MMM; Maul LV; Heinzerling L; Heppt MV; Colapietro C; Rusch J; Blome C
J Cancer Res Clin Oncol; 2024 May; 150(5):252. PubMed ID: 38743104
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the pharmacokinetics and metabolism of pembrolizumab in the treatment of melanoma.
Longoria TC; Tewari KS
Expert Opin Drug Metab Toxicol; 2016 Oct; 12(10):1247-53. PubMed ID: 27485741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]